John H. Johnson has been appointed chairman of the Cortendo AB board of directors and Richard Kollender named a director. The appointments were proposed by the nomination committee and approved by shareholders during the Extraordinary General Meeting on March 17.
“We welcome the additions of John and Rich to Cortendo’s board of directors,” said Matthew Pauls, president and chief executive officer of Cortendo. “John and Rich bring extensive global biopharmaceutical industry experience to Cortendo, and we look forward to their respective contributions to the company as we continue to grow our orphan endocrine franchise, and expand into other therapeutic areas in the rare disease space.”
Johnson has more than 30 years of biopharmaceutical industry experience at leading global organizations, including Johnson & Johnson, Eli Lilly & Company, ImClone and Pfizer, Inc. “I look forward to leveraging my experience in commercializing innovative products to help Cortendo make a difference in the lives of people with rare diseases, including Cushing’s syndrome,” he said.
Kollender, who is trained as a certified public accountant, has significant biopharmaceutical experience in executive management, venture capital and as a director on public and private company boards.
Source: PR Newswire